The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism.
Cell · 2016
Last updated 2026-05-28The study found that different GLP-1 drugs can activate the GLP-1 receptor in distinct ways, leading to varied effects inside cells. By analyzing how these drugs interact with the receptor's surface, researchers identified specific regions that influence these differences, which could help design more targeted medications in the future.
AI summary of the abstract below.
| Journal | Cell, 2016 |
|---|---|
| Citations | 132 |
| Relative citation ratio | 4.81 |
| NIH percentile | 92 |
| Molecules | — |
Abstract
Ligand-directed signal bias offers opportunities for sculpting molecular events, with the promise of better, safer therapeutics. Critical to the exploitation of signal bias is an understanding of the molecular events coupling ligand binding to intracellular signaling. Activation of class B G protein-coupled receptors is driven by interaction of the peptide N terminus with the receptor core. To understand how this drives signaling, we have used advanced analytical methods that enable separation of effects on pathway-specific signaling from those that modify agonist affinity and mapped the functional consequence of receptor modification onto three-dimensional models of a receptor-ligand complex. This yields molecular insights into the initiation of receptor activation and the mechanistic basis for biased agonism. Our data reveal that peptide agonists can engage different elements of the receptor extracellular face to achieve effector coupling and biased signaling providing a foundation for rational design of biased agonists.
Verbatim abstract via PubMed 27315480 ↗